Ascendis Pharma A/S vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.75. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| ASND | QDTE | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $277.18 | $36.60 |
52-Week Low | $189.74 | $26.85 |
Enterprise Value | $17.04B | — |
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →